Neil K. Warma, President & CEO, Opexa Therapeutics, discusses how Opexa’s research into the first personalized therapy for patients with multiple sclerosis (MS) could have much broader applications as a platform technology. The technology from Opexa’s drug, Tcelna, which targets specific identified pathogenic T-cells in patients with secondary progressive MS, could be leveraged to target other diseases as well.